Prognostic Value of P-glycoprotein and Proliferative Index in Advanced Low Grade Serous Ovarian Carcinomas

REFERENCES

• Gerlach JH, Kartner N, Bell DR, Ling V. Multidrug resis-tance. Cancer Surg 1986; 5: 25.
   PubMedGoogle Scholar
• Beck WT. The cell biology of multiple drug resistance. Biochem Pharmacol 1987; 36: 2879.
   PubMed Web of Science ®Google Scholar
• Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987; 316: 1388.
   PubMed Web of Science ®Google Scholar
• Friedland ML. Prognostic factors in ovarian cancer. Sem Oncol 1998; 25 (3): 305–314.
   PubMed Web of Science ®Google Scholar
• Izquierdo MA, van der Zee AGJ, Vermorken JB, et al. Drug resistance-associated marer Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230–1237.
   PubMed Web of Science ®Google Scholar
• Brown DC, Gaffer KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990; 17: 489–503.
   PubMed Web of Science ®Google Scholar
• Zhai YL, Kobayashi Y, Mori A, et al. Expression of steroid receptor, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol 1999; 18: 20–28.
   PubMed Web of Science ®Google Scholar
• Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA. Maximum Ki-67 staining in prostate cancer provides indepen-dent prognostic information after radical prostatectomy. Anticancer Res 2001; 21: 4071-4076.
   Google Scholar
• Rodriguez-Alonzo A, Pita-Fernandez S, Gonzales-Carrero J, Nogueira-March JL. Multivariate analysis of sur-vival, recurrence, progression and development of metastasis in Ti and T2a transitional cell bladder carcinoma. Cancer 2002; 94 (6): 1677–1684.
   PubMed Web of Science ®Google Scholar
• Villena-Heinsen C, Meyberg R, Axt-Fliedner R, Reitnauer K, Reichrath J, Friedrich M. Immunohistochemical analysis of 1,25-dihydroxyvitamin-D3-receptor, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma. Anticancer Res 2002; 22 (4): 2261–2267.
   PubMed Web of Science ®Google Scholar
• FIGO Cancer Committee. Stage grouping for primary carcinoma of the ovary. Gynecol Oncol 1986; 25: 383–385.
   Google Scholar
• De Vita VT, Hellman S, Rosemberg SA. Cancer, Principles e Practice of Oncology. 5th Edition, Lippincott - Raven, Philadelphia - New York, 1997: 333-347.
   Google Scholar
• Markman M, Bookman MA. Second line treatment of ovarian cancer. Oncologist 2000; 5 (1): 26–35.
   PubMedGoogle Scholar
• Markman M. Role of chemotherapy in the manage-ment of ovarian cancer. Expert Rev Anticancer Ther 2002; 2 (1): 90–96.
   PubMedGoogle Scholar
• Stata Press: Statistics-Stata 7. Reference Q-ST. 4905 Lakeway Drive, College Station, Texas 77845, 2000.
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life tables (with discus-sion). J R Stat Soc B. 1972; 34: 187–202.
   Google Scholar
• Johnson SW, Ozols RF, Hamilton TC. Mechanisms of drug resistance in ovarian cancer. Cancer 1993; 71: 644–649.
   PubMed Web of Science ®Google Scholar
• Parekh H, Wiesen K, Simpkins H. Acquisition of taxol resistance via P-Glycoprotein and non-P-Glycoprotein-mediat-ed mechanisms in human ovarian carcinoma cells. Biochem Pharmacol 1997; 53 (4): 461–470.
   PubMed Web of Science ®Google Scholar
• Heike Y, Tsuro T. Antibody in the study of multiple drug resistance. Cytotechnology 1993; 12: 91–107.
   PubMed Web of Science ®Google Scholar
• Rubin S, Finstad CL, Hoskins WJ, et al. Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. Am J Obstet Gynecol 1990; 163: 69–73.
   PubMed Web of Science ®Google Scholar
• Mcgown AT, Murphy D, Swindell R, Crowther D, Fox BW. Correlation of drug resistance-associated parameters in ovarian tumor biopsies. Int J Gynecol Cancer 1994; 4: 241–249.
   PubMed Web of Science ®Google Scholar
• Joncourt F, Buser K, Altermatt H, Bacchi M, Oberli A and Cerny T. Multiple drug resistance parameter expression in ovarian cancer. Gynecol Oncol 1998; 70: 176–182.
   Google Scholar
• Arts HJG, Katsaros D, de Vries EGE, et al. Clin Cancer Res 1999; 5: 2798–2805.
   PubMed Web of Science ®Google Scholar
• Schondorf T, Scharl A, Kurbacher CM, et al. Amplification of the mdrl-gene is uncommon in recurrent ovarian carcinomas. Cancer Lett 1999; 146: 195–199.
   PubMed Web of Science ®Google Scholar
• Ohishi, Y, Oda Y, Schiumi T, et al. ATP-binding cas-sette superfamily transporter gene expression in human prima-ry ovarian carcinoma. Clin Cancer Res 2002; 8: 3767–3775.
   PubMed Web of Science ®Google Scholar
• Khalifa MA, Abdoh AA, Mannel RS, Walker JL, Angros LH, Min K. P-glycoprotein as a prognostic indicator in pre- and postchemotherapy ovarian adenocarcinoma. Int J Gynecol Pathol 1997; 16: 69–75.
   PubMed Web of Science ®Google Scholar
• Baekelandt MM, Holm R, Nesland JM, Tropè CG, Kristensen GB. P-glycoprotein expression is a marker for chemotherapy, resistance and prognosis in advanced ovarian cancer. Anticancer Res 2000; 20: 1061–1068.
   PubMed Web of Science ®Google Scholar
• Galani E, Sgouros J, Petropoulou C, et al. Correlation of MDR1, nm23-H1 and H Sema gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients. Anticancer Res 2002; 22: 2275-2280.
   Google Scholar
• Arao S, Sura H, Mandai M, et al. Expression of mul-tidrug resistance gene and localizzation of P-glycoprotein in Human primary ovarian cancer. Cancer Res 1994; 54: 1355–1359.
   PubMed Web of Science ®Google Scholar
• Raspollini MR, Pinzani P, Pazzagli M, et al. Multidrug Resistance in ovarian cancer: comparisong an immunocyto-chemical study and ATP-tumor chemosensitivity assay. J Chemother 2002; 14 (5): 518–525.
   PubMed Web of Science ®Google Scholar
• Garzetti GG, Ciavattini A, Goteri G, et al. Ki67 anti-gen immunostaining (MIB1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol Oncol 1995; 56 (2): 169–174.
   PubMed Web of Science ®Google Scholar
• Viale G, Maisonneuve P, Bonoldi E, et al. The com-bined evaluation of p53 accumulation and of Ki67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients. Ann Oncol 1997; 8 (5): 469–476.
   PubMed Web of Science ®Google Scholar
• Gotlieb WH, Goldberg I, Weisz B, et al. Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer. Gynecol Oncol 2001; 82 (1): 99–104.
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Vassilopoulos I, Konstantinidou AE, et al. The combined evaluation of p27Kipl and Ki-67 expres-sion provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol 2002; 85 (3): 404–414.
   PubMed Web of Science ®Google Scholar
• Villena-Heinsen C, Meyberg R, Axt-Fliedner R, Reitnauer K, Reichrath J, Friedrich M. Immunohistochemical analysis of 1,25-dihydroxyvitamin-D3-receptor, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma. Anticancer Res 2002; 22 (4): 2261–2267.
   PubMed Web of Science ®Google Scholar
• Itamochi H, Kigawa J, Sugiyama T, Kikuki Y, Suzuki M, Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002; 100: 281–287.
   PubMed Web of Science ®Google Scholar